Drug Development

Luban, J., Sattler, R., Mühlberger, E., Graci, J.D., Cao, L., Weetall, M., Trotta, C., Colacino,J.M., Bavari, S., Strambio-De-Castillia, C., Suder, E.L., Wang, Y., Soloveva, V., Cintron-Lue, K., Naryshkin, N.A., Pykett, M., Welch, E.M., O’Keefe, K., Kong, R., Goodwin, E., Jacobson, A., Paessler, S., and Peltz, S. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Research 292:198246, 2021.

Cao, L., Weetall, M., Trotta, C., Cintron, K., Ma, M., Kim, M.-J., Furia, B., Romfo, C.,  Graci, J.D., Li, W., Du, J., Sheedy, J., Hedrick, J., Risher, N., Yeh, S., Qi, H., Arasu, T., Hwang, S., Lennox, W., Ingolia, N.T., Kong, R., Petruska, J., Moon, Y.-C., Babiak, J.,  Almstead, N.G., Davis, T.W., Jacobson, A., Branstrom, A., Colacino, J.M., and Peltz, S.W. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Molec. Cancer Therap. 18: 3-16, 2019.

Welch, E.M., Barton, E.R., Zhuo, J., Tomizawa, Y, Friesen, W.J., Trifillis, P., Paushkin, S.,  Patel, M., Trotta, C.R., Hwang, S., Wilde, R.G., Karp, G., Takasugi, J., Chen, G., Jones, S., Ren, H., Moon, Y.-C., Corson, D., Turpoff, A.A., Campbell, J.A., Conn, M.M., Khan, A.,  Almstead, N.G., Hedrick, J., Molin, A., Risher, N., Weetall, M., Yeh, S., Branstrom, A.A.,  Colacino, J.M., Babiak, J., Ju, W.D., Hirawat, S., Northcutt, V.J., Miller, L.L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S.W., & Sweeney, H.L. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91, 2007.